Fig. 5: Plasma concentrations of RAY1216 and PF-07321332 after i.v. injection dosing and gavage (p.o.) dosing in mouse and rat models. | Nature Microbiology

Fig. 5: Plasma concentrations of RAY1216 and PF-07321332 after i.v. injection dosing and gavage (p.o.) dosing in mouse and rat models.

From: Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir

Fig. 5

a, The pharmacokinetics in the mouse models. b, The pharmacokinetics in the rat models. In each dosing experiment, male (circles and diamonds) and female (squares and triangles) animal groups were tested. Each group consisted of five animals, and the data of each animal are shown with group average values connected by lines. The red dashed lines represent the lower limit of quantitation (LLOQ, 1 ng ml−1) of plasma drug concentration.

Source data

Back to article page